15.55
-0.82(-5.01%)
Currency In USD
| Previous Close | 16.37 |
| Open | 16.42 |
| Day High | 16.48 |
| Day Low | 15.53 |
| 52-Week High | 22.5 |
| 52-Week Low | 8.58 |
| Volume | 1.66M |
| Average Volume | 2.26M |
| Market Cap | 1.34B |
| PE | -4 |
| EPS | -3.89 |
| Moving Average 50 Days | 12.75 |
| Moving Average 200 Days | 12.84 |
| Change | -0.82 |
If you invested $1000 in Syndax Pharmaceuticals, Inc. (SNDX) since IPO date, it would be worth $1,295.83 as of September 13, 2025 at a share price of $15.55. Whereas If you bought $1000 worth of Syndax Pharmaceuticals, Inc. (SNDX) shares 5 years ago, it would be worth $919.57 as of September 13, 2025 at a share price of $15.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Syndax Announces Participation in September Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as memb
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
GlobeNewswire Inc.
Jul 28, 2025 11:00 AM GMT
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
GlobeNewswire Inc.
Jun 24, 2025 8:01 PM GMT
– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia – NEW YORK, June